Abstract Number: 2001 • ACR Convergence 2022
Cardiovascular Risk Factors and Therapeutic Outcome in Rheumatoid Arthritis – Real World Data
Background/Purpose: Sustained targeted therapeutic outcome with biological therapy in real clinical conditions is not yet achievable in a large proportion of rheumatoid arthritis (RA) patients.…Abstract Number: 2138 • ACR Convergence 2022
Real-world Persistence and Treatment Patterns in Psoriatic Arthritis Patients Treated with Anti-IL17 Therapy
Background/Purpose: Interleukin-17A inhibitors (anti-IL17) have provided an additional treatment option in the management of the psoriatic arthritis (PsA). This study aims to describe the patient…Abstract Number: 0259 • ACR Convergence 2022
Impact of Comorbidity on Disease Activity and Functional Status in Patients with Rheumatoid Arthritis Receiving Biologic DMARDs, a Longitudinal Analysis of the KOBIO-RA
Background/Purpose: This study aims to evaluate the impact of comorbidities on disease activity and functional disability in patients with RA treated with biological disease-modifying anti-rheumatic…Abstract Number: 0352 • ACR Convergence 2022
The Effect of Belimumab (BEL) on Kidney Outcomes in SLE: Results of a Large Integrated Analysis
Background/Purpose: BEL, an approved SLE treatment,1 improved kidney outcomes in initial Phase 3 SLE trials.2,3 This post hoc analysis evaluates the effect of BEL on…Abstract Number: 0465 • ACR Convergence 2022
Tocilizumab in Large-Vessel Giant Cell Arteritis and Takayasu Arteritis: Multicentric Observational Comparative Study
Background/Purpose: Tocilizumab (TCZ) has shown to be effective for large vessel vasculitis including giant cell arteritis (GCA) and Takayasu arteritis (TAK). However, LVV-GCA and TAK…Abstract Number: 0782 • ACR Convergence 2022
Low Circulating B Cells Correlate with Unresponsiveness to COVID-19 Vaccination Among Patients Treated with Rituximab
Background/Purpose: Rituximab impairs humoral immunity by depleting CD20+ B cells. Previous studies have demonstrated that patients on rituximab have decreased immune response to COVID-19 vaccination.…Abstract Number: 0900 • ACR Convergence 2022
Effect of Biologic Agents on Lipid Levels and Cardiovascular Risk in Rheumatoid Arthritis Patients
Background/Purpose: Cardiovascular (CV) risk in RA is increased due to interaction between traditional risk factors and systemic inflammation. The purpose of this analysis was to…Abstract Number: 1044 • ACR Convergence 2022
Combined Biological or Targeted Therapy in Spondyloarthritis: Experience from a Multicenter Case Series in Spain
Background/Purpose: Combined biological or targeted therapy (CBTT) is rarely considered in clinical practice due to contraindication in guidelines, potential safety concerns and high costs. However,…Abstract Number: 1417 • ACR Convergence 2022
Clinical and Demographic Characteristics of Patients with RF+/ACPA+ RA and First-Line TNF Inhibitor versus Abatacept Treatment Choice in Real-World Clinical Practice
Background/Purpose: Early intensive treatment (tx) is an accepted paradigm in the tx of patients (pts) with RA with poor prognostic factors (eg, RF/ACPA seropositivity); however,…Abstract Number: 1597 • ACR Convergence 2022
Achievement of Different Treatment Targets with Izokibep Demonstrates Efficacy Benefits in Patients with Active Psoriatic Arthritis: Results from a 16-Week Randomized, Placebo-Controlled Phase 2 Clinical Trial
Background/Purpose: Psoriatic arthritis (PsA) is a chronic, inflammatory disease with multiple clinical manifestations (arthritis, spondylitis, enthesitis, dactylitis, skin, nails). IL-17 inhibitors have shown efficacy across…Abstract Number: 2002 • ACR Convergence 2022
Do SMS and Email Reminders Increase the Rate of Seasonal Influenza Vaccination in RA Patients Treated with Biologics: A Nested Randomized Controlled Trial Within the ART Registry?
Background/Purpose: In patients treated with biologics, vaccination against influenza is recommended. However, vaccination coverage remains very low. The use of automatic digital reminders is an…Abstract Number: 2139 • ACR Convergence 2022
Sustained Response to Guselkumab Regardless of Baseline Demographic, Disease, and Medication Characteristics in Patients with Active Psoriatic Arthritis and an Inadequate Response to TNF Inhibitors: Results from a Phase 3b Trial
Background/Purpose: Guselkumab (GUS) is a human monoclonal antibody targeting the IL-23 p19 subunit. In the Phase 3b COSMOS trial (NCT03796858), GUS significantly improved disease signs/symptoms…Abstract Number: 0260 • ACR Convergence 2022
Impacts of Poor Prognostic Factors in Rheumatoid Arthritis on Clinical Outcomes and Treatment Choices from an Observational Cohort of Korean Patients with Rheumatoid Arthritis
Background/Purpose: The primary target for the treatment of rheumatoid arthritis (RA) is achieving remission or low disease activity with proper use of DMARD. Besides controlling…Abstract Number: 0359 • ACR Convergence 2022
Attainment of Remission with Anifrolumab: A Post Hoc Analysis of Pooled TULIP-1 and TULIP-2 Datasets
Background/Purpose: In patients with SLE, achieving remission is a treat-to-target goal. Remission is associated with lower rates of hospitalization and damage accrual and better quality…Abstract Number: 0474 • ACR Convergence 2022
Utility of Optimization of Tocilizumab Therapy in Giant Cell Arteritis: A Multicenter Study of 471 Patients
Background/Purpose: Tocilizumab (TCZ) has shown to be useful in the treatment of large-vessel vasculitis, including giant cell arteritis (GCA). There is general agreement on the…
- « Previous Page
- 1
- …
- 27
- 28
- 29
- 30
- 31
- …
- 54
- Next Page »